Quadrivalent VLP Vaccine

BIOLOGICAL3 trials

Sponsors

Novavax, Medicago

Conditions

InfluenzaRNA Virus InfectionsRespiratory Tract DiseasesRespiratory Tract InfectionsVirus Diseases

Phase 2

Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults

CompletedNCT02307851

NovavaxInfluenza

Start: 2014-11-30End: 2015-06-30Updated: 2016-09-23

Phase 3

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

CompletedNCT03301051

MedicagoInfluenza, Respiratory Tract Diseases, Respiratory Tract Infections +2

Start: 2017-08-31End: 2018-05-09Updated: 2023-08-14

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

CompletedNCT03739112

MedicagoRespiratory Tract Diseases, Respiratory Tract Infections, RNA Virus Infections +1

Start: 2018-09-18End: 2019-07-16Updated: 2023-06-23

Related Papers

Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials.

2020-10-13139 citations

Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-Two randomized Phase II clinical trials in 18 to 49 and ≥50 years old adults.

2019-06-0585 citations